November 20, 2026
Source: drugdu
42

On November 19, Luye Pharma (02186) announced that China’s National Medical Products Administration had approved Ruoxinlin® (toludesvenlafaxine hydrochloride extended-release tablets), its in-house Class 1 innovative drug, for generalized anxiety disorder. This is the product’s second approved indication in China, following its initial approval for depression in November 2022.
The company said the drug improves anxiety symptoms and supports patients’ overall condition and social functioning, with favorable overall safety and tolerability. The new indication broadens the product’s clinical use.
Source: http://finance.eastmoney.com/a/202611193935196418.html
By editoryour submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.